Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation

被引:89
作者
Griffith, LM
McCoy, JP
Bolan, CD
Stroncek, DF
Pickett, AC
Linton, GF
Lundqvist, A
Srinivasan, R
Leitman, SF
Childs, RW
机构
[1] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA
[2] NHLBI, Dept Transfus Med, NIH, Bethesda, MD 20892 USA
[3] NHLBI, Warren G Magnuson Clin Ctr, NIH, Core Flow Cytometry Facil, Bethesda, MD 20892 USA
[4] NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA
关键词
plasma cells; chimaerism; major ABO incompatible transplantation; non-myeloablative allogeneic transplantation;
D O I
10.1111/j.1365-2141.2005.05364.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Delayed donor erythropoiesis and pure red-cell aplasia (PRCA) complicate major-ABO mismatched non-myeloablative allogeneic stem-cell transplantation. To characterize these events, we analysed red-cell serology and chimaerism in lymphohaematopoietic lineages, including plasma cells and B cells, in 12 consecutive major-ABO incompatible transplants following cyclophosphamide/fludarabine-based conditioning. Donor erythropoiesis was delayed to more than 100 days in nine (75%) patients including six (50%) who developed PRCA. During PRCA, all patients had persistent anti-donor isohaemagglutinins and recipient plasma cells (5-42%), while myeloid and T cells were completely donor in origin. In contrast, B-cell chimaerism was frequently full-donor when significant anti-donor isohaemagglutinins persisted. Four patients with early mixed haematopoietic chimaerism and the prolonged presence of anti-donor isohaemagglutinins and recipient plasma cells developed delayed-onset (>100 days post-transplant) red cell transfusion dependence and PRCA after myeloid chimaerism converted from mixed to full donor. These findings confirm that donor-erythropoiesis is impacted by temporal disparities in donor immune-mediated eradication of recipient lymphohaematopoietic cells during major-ABO incompatibility and suggest that plasma cells are relatively resistant to graft-versus-host haematopoietic effects.
引用
收藏
页码:668 / 675
页数:8
相关论文
共 27 条
[1]   Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: Recommendations from a Workshop at the 2001 Tandem Meetings [J].
Antin, JH ;
Childs, R ;
Filipovich, AH ;
Giralt, S ;
Mackinnon, S ;
Spitzer, T ;
Weisdorf, D .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (09) :473-485
[2]   Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens [J].
Bellucci, R ;
Wu, CJ ;
Chiaretti, S ;
Weller, E ;
Davies, FE ;
Alyea, EP ;
Dranoff, G ;
Anderson, KC ;
Munshi, NC ;
Ritz, J .
BLOOD, 2004, 103 (02) :656-663
[3]  
Benjamin R J, 1998, Biol Blood Marrow Transplant, V4, P151
[4]   Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients [J].
Berentsen, S ;
Ulvestad, E ;
Gjertsen, BT ;
Hjorth-Hansen, H ;
Langholm, R ;
Knutsen, H ;
Ghanima, W ;
Shammas, FV ;
Tjonnfjord, GE .
BLOOD, 2004, 103 (08) :2925-2928
[5]  
Bolan CD, 2002, BLOOD, V99, P4643
[6]   Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation [J].
Bolan, CD ;
Leitman, SF ;
Griffith, LM ;
Wesley, RA ;
Procter, JL ;
Stroncek, DF ;
Barrett, AJ ;
Childs, RW .
BLOOD, 2001, 98 (06) :1687-1694
[7]   From the bench to the bedside: ways to improve rituximab efficacy [J].
Cartron, G ;
Watier, H ;
Golay, J ;
Solal-Celigny, P .
BLOOD, 2004, 104 (09) :2635-2642
[8]   Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors [J].
Carvallo, C ;
Geller, N ;
Kurlander, R ;
Srinivasan, R ;
Mena, O ;
Igarashi, T ;
Griffith, LM ;
Linehan, WM ;
Childs, RW .
BLOOD, 2004, 103 (04) :1560-1563
[9]   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses [J].
Childs, R ;
Clave, E ;
Contentin, N ;
Jayasekera, D ;
Hensel, N ;
Leitman, S ;
Read, EJ ;
Carter, C ;
Bahceci, E ;
Young, NS ;
Barrett, AJ .
BLOOD, 1999, 94 (09) :3234-3241
[10]   Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J].
Childs, R ;
Chernoff, A ;
Contentin, N ;
Bahceci, E ;
Schrump, D ;
Leitman, S ;
Read, EJ ;
Tisdale, J ;
Dunbar, C ;
Linehan, WM ;
Young, NS ;
Barrett, AJ ;
Clave, E ;
Epperson, D ;
Mayo, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) :750-758